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Abstract 
 
Peripheral monocytes from patients with common variable immunodeficiency (CVID) had 
on average a 2 fold greater tendency to form giant cells in medium without additional 
cytokines. Giant cell formation was faster and 3 to 5 fold higher in most CVID cells 
compared to normal. Addition of IL4, GMCSF, IFNγ, TNFa and both T cell and monocyte 
conditioned media promoted monocyte fusion of some CVID individuals over 5 fold the 
normal average level, with combinations of cytokines and monokines acting 
synergistically.  The reduction of normal giant cell formation by anti-IFNγ antibody and a 
greater tendency of CVID cells to fuse in immunoglobulin conditioned media suggests 
that standard IVIg treatment contributes to granuloma formation. CVID and normal giant 
cells expressed similar levels of phenotypic molecules and had similar phagocytic 
activity. Monocytes from many CVID patients have an elevated tendency to fuse which 
may explain the high incidence of granulomatous complications in CVID. 
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Introduction  
Multinucleated cells are observed regularly in the immune response to malignancy 
(Cohen and  Kurzrock, 2007), and some microbial and parasitic diseases (El-Zammar 
and Katzenstein, 2007). First reported in patients with tuberculosis over a century ago, 
multinucleated giant cells are formed by macrophage fusion (Kreipe et al., 1988) and 
represent an end-point in myeloid cell lineage development. Giant cells are a regular 
feature of the immune response to diseases characterised by pathogen survival in 
phagocytes, such as leprosy, syphilis and aspergillosis (Segal et al., 1998); they are also 
a component of chronic inflammatory reactions to parasites, including schistosomiasis, 
Leishmania and Filaria (Bentley et al., 1985). Non-caseating epithelioid cell granulomas 
occur in about 10% of patients with Hodgkin’s lymphoma, and less frequently in other 
malignant conditions (Brincker,1986), particularly lung, prostate and some skin tumours 
(Kornacker et al., 2002; Kurata et al., 2005). 
 
Granulomatous reactions centred round multinucleate giant cells are a pathological 
feature of a variety of inflammatory diseases, including sarcoidosis, Crohn’s disease and 
rheumatoid arthritis (Barnard and Newman, 2001). Epithelioid or giant cells, which form 
the centre of granulomatous reactions, are generated in these diseases from 
macrophages by the action of inflammatory cytokines (Kasahara et al., 1989). 
Granulomatous reactions are a recognised feature of common variable 
immunodeficiency (CVID) with about 20% of patients developing unexplained chronic 
inflammation, often with granuloma formation, involving many different organs, most 
commonly the spleen, lymph nodes, liver or lungs (Ardeniz and Cunningham-Rundles, 
2009; Bates et al., 2004). Although recurrent bacterial infections due to failure of 
antibody production is the predominant clinical problem in CVID, the circulating T cells 
and monocytes in many patients show features of persistent activation (Holm et al., 
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2006), with evidence that herpes viruses provide a major inflammatory stimulus in some 
patients (Marashi et al., 2012). CVID monocytes generally generate defective dendritic 
cells with deficient major histocompatibility complex (MHC) class II DR expression 
(Scott-Taylor et al., 2004) which induce poor T cell proliferation and abnormal cytokine 
production (Bavry et al., 2005; Cunningham-Rundles and Radigan, 2005). Abnormal 
monocyte responses may contribute to a polarised Th1 immune phenotype in CVID, with 
exacerbated T cell IL-12 production (Cambronero et al., 2000) and increased IL-12 
receptor expression (McQuaid et al., 2000), promoting a high incidence of 
granulomatous infiltration of lymphoid and other tissues (Webster, 2001). In this study, 
we have investigated the formation of giant cells from CVID monocytes, which could 
explain the abnormally high rate of granuloma formation in CVID and elucidate the 
process of inflammatory polarisation in some CVID individuals.  
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Materials and Methods 
Patients 
Twenty five 24 patients (18 females, 6 males, mean age 49yrs, range 26-75 yrs.) 
attending the Royal Free clinic with a diagnosis of Common Variable Immunodeficiency 
(CVID) based on IUIS criteria (Conley et al., 1999) (Table 1). Blood samples were 
obtained prior to immunoglobulin therapy from patients with no clinical symptoms of 
infection. Healthy adult volunteers (9 females, 7 males, mean age 40yrs, range 22-66yrs) 
provided blood samples. Patient and control blood donors were healthy and free from 
overt signs of infection at the time of donation. All donors gave informed consent and the 
study had local ethical approval (ref: 04/Q0501/119). 
 
Cell Culture 
Peripheral blood was collected in lithium heparin tubes, mixed with an equal volume of X 
vivo 15 medium (Cambrex Bio Science, Wokingham) and mononuclear cells (PBMCs) 
separated on Lymphoprep (Axis-Shield ProC As, density 1.077 g/ml) after centrifugation.  
Plasma supernatants were collected, clarified by centrifugation at 500 x g and used to 
culture autologous cells. PBMCs were washed twice in medium to reduce platelets and 
then seeded into 6 well plates (Nunc 152795, Sigma-Aldrich, Poole, Dorset). Routine 
monitoring of immunologic parameters was performed by the Clinical Immunology 
Service of the Royal Free Hospital using isotype controls in parallel with each batch of 
samples analyzed. Peptide stimulation of T cells was performed on fresh PBMCs 
stimulated with 10 mg/mL CMV or EBV peptides or without peptide in the presence of 
anti-CD28 (10 mg/mL) antibody and brefeldin A (10 mg/mL, Sigma-Aldrich) as previously 
described (Marashi et al., 2012). PBMCs were stained with the appropriate HLA 
pentamer (10 mg/mL) for 15 minutes at room temperature, washed with PBS containing 
0.1% sodium azide, stained for 15 minutes at room temperature with CD8 FITC and PD-
1 APC antibodies (Pharmingen 551347 and 558694), fixed and permeabilized (Fix & 
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Perm Kit, GAS-002, Caltag Medsystems) and stained with a PE-conjugated antibody to 
granzyme B (Pharmingen, 561142). T cell clonal analysis was performed immediately on 
a FACSCalibur flow cytometer using a minimum of 50,000 events. Individuals with a 
>1% total T cell reactivity with CMV tetrameric reagents were designated CMV positive 
(Table 1).   
 
Adherent monocytes were selected in 2 successive 2 hr. incubations in 6 well plates, 
from which non adherent cells were carefully washed off and adherent cells eluted by 
incubation with 5mM EDTA for use in fusion assays. CD14+ monocytes were purified to 
<98% using an MS column (130-042-201, Miltenyi Biotech, Bisley, Surrey) containing 
magnetic sheep anti-mouse IgG coated beads (Dynal Biotech, 120-000-305) incubated 
with 1 ug/ml CD14 antibody (BD PharMingen, San Jose, CA, 550376) for 30 minutes. B 
lymphocytes (>95% purity) were selected with CD19+ magnetic beads (Miltenyi 
Biotech,130-052-201) from the non-adherent cell fraction before T lymphocytes (> 98% 
CD3+ purity by flow cytometry) were separated by 2 rounds of negative selection using a 
mixed antibody (Miltenyi Biotech, 130-091-156). CD14+ monocytes were cultured in X 
vivo 15 medium with 10% autologous plasma or 10% heat treated (56°C for 30 min) AB 
serum (Sera-Lab S-11-J, Haywards Heath, West Sussex) at a density of 5 x105 per ml at 
37°C in a humidified atmosphere containing 5% CO2 with a variety of cytokines and 
mitogens for 7 days. TNF, IFN or IL1 (5 to 50 ng/ml, Peprotech EC, London) were 
added to some cultures; some culture wells were coated with 10% BSA or type-
1collagen (Sigma-Aldrich, C3867) in coating buffer (50mM Na2CO3, pH = 9.5) overnight 
at 4°C. Cell viability was monitored by trypan blue exclusion and media including 
cytokine reagents changed every third day of culture. LPS contamination of media 
contamination of media (Limulus Amoeba Lysate kit, Quadratech Ltd, Epsom, Surrey) 
was below 15 ng/ml.  
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T cell conditioned media were generated from normal and CVID T lymphocytes 
incubated overnight in 6 well plates at a density of 1 x107 cells per ml with 1 ug/ml PHA 
(nPHA and cPHA, respectively) or in wells coated with 20 ug/ml anti-CD3 antibody 
(nCD3 and cCD3). Antibody coated plates were washed three times with cation-free 
phosphate buffered saline before use. Normal and CVID monocyte conditioned media 
was collected from 1x 107 pooled purified CD14+ normal and patient cells incubated 
overnight in 6 well plates coated with 10 mg/mL human gamma globulin (Sandoglobulin, 
CSL Behring, Haywards Heath) (nIVIG and cIVIG, respectively) or 200 nmol/mL phorbol 
myristate acetate (Sigma Aldrich) (nPMA and cPMA, respectively). Cell supernatant was 
clarified by centrifugation for 10 minutes at 500 xg, passed through 0.2 um non-
pyrogenic syringe filters and stored at -70°C in 1 ml aliquots. The cell- free conditioned 
medium was added to monocyte or PBMC cultures at a final concentration of 50% in at 
least 3 experiments with different conditioned media. 
 
Immature monocyte derived dendritic cells (MdDC) were generated from adherent 
monocytes after 6 days of culture in X vivo 15 supplemented with 20% autologous 
plasma, 100 ng/ml GM CSF and 50 ng/ml IL4 (PeproTech EC, London, AF-300-03 and 
AF-200-04). MdDC were washed and applied to poly-L-lysine (P4832, Sigma-Aldrich, 
Poole Dorset) treated glass coverslips in 200 ul drops of fresh X vivo 15 at 106  cell/ml in 
6 well plates. After 1 hour incubation in a humidified chamber, coverslips were gently 
submerged in 3 ml of X vivo 15 medium supplemented with 100 ng/ml GM CSF and 50 
ng/ml IL4.  
 
The influence of maturation and differentiation agents on giant cell formation was 
investigated with or without autologous plasma with the addition of cytokines; GM CSF or 
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G CSF, (Peprotech EC, AF-300-23, 100 ng/ml), IL4 and TNF (Peprotech EC, AF-300-
01a, 20 ng/ml), IFN (5-20 ng/ml), IL1 (10 ng/ml), IL10 (5 and 10 ng/ml) (Peprotech EC, 
AF-300-02, AF-200-01a and AF-200-10) or mitogens PMA and PHA (2.5-10 ng/ml, 
P1585 and L2769, Sigma–Aldrich) added at various times to different cultures. CD3 
antibody (OKT3 cell supernatant) was used to coat some wells at 5 ug/ml in phosphate 
buffer overnight prior to the addition of cells. Anti-IFN antibody (Remicade, 100 mg/ml) 
was added to cytokine cultured cells at a concentration of 1 ug/ml for 5 days prior to 
harvest. Wells were flooded and media exchanged gently by pipette to minimise 
disturbance throughout. At various time points as described, cells were fixed in ice cold 
2% paraformaldehyde PBS for 30 minutes at 4°C and stained with Wright Giemsa stain. 
To investigate the effect of differentiation on fusion, cell were preincubated for 15 
minutes in X vivo 15 medium without FBS in 10 uM phalloidin FITC, phalloidin oleate and 
5 to 40 mM cytochalasin D (Sigma-Aldrich, P5282, P9992 and C2618) prior to washing 
twice in PBS. incubated in 6 well plates in different concentrations of IL4 and GM CSF 
between 20 and 100 mM for various times before cells were centrifuged at 180 xg for 10 
minutes at 1 x 105 cell per ml in 24 well plates over poly L lysine coated coverslips, 
submerged, cultured overnight, fixed in paraformaldehyde, and stained with Wright 
Giemsa. Stained cells were examining using a 20x objective lens and an eyepiece 
graticule, counting the number of nuclei within giant cells containing more than one 
nucleus and the total number of nuclei in a given area of the cell sheet. The fusion index 
(FI) was calculated according to the following formula: FI (%) = (number of nuclei within 
giant cells)/ (total number of nuclei counted) x100. Between 300 and 500 nuclei from 
selected representative fields were counted for each experiment. Phase contrast and 
fluorescence photographs were taken with an inverted fluorescence Olympus IMT-2 
microscope.  
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Phagocytosis 
Saccharomyces cerevisiae was grown in 10% FBS/RPMI 1640 overnight at 37°C, 
washed in RPMI, fixed in Leukoperm (Serotec, BUFO9B) and stained with 10 mg/ml 
ethidium bromide in PBS for 10 minutes. Yeast were washed twice each in DMSO and 
PBS and resuspended in PBS at 1x 108/ml. Yeast and PE conjugated carboxylated 
beads (6 um diameter, Molecular Probes, Oregon) were added to monocyte cultures on 
day 6 at a ratio of 10:1 cell. Attached unincorporated beads and yeast were removed 
prior to FACS analysis by treatment with 0.5% trypsin in PBS at 37°C for 5 minutes or 
cold DMSO for 5 minutes.  
 
Giant Cell Ultrastructure And Expression 
Surface expression of giant cells was examined in cells fixed in 1% PFA/PBS for 15 
minutes and permeabilized with 0.01% saponin (Sigma-Aldrich, 47036) in 1% mouse 
serum/PBS for 15 minutes at 4ºC and rinsed twice with excess PBS. Non specific sites 
were blocked by incubation in 5ug/ml mouse serum/1% BSA/PBS for 30 mi at 37°C 
before cells were washed and stained with FITC-conjugated mouse anti-human 
antibodies to MHC II DR, CD83, CD14 (BD Pharmingen 555560, 556855 and 555398, 
respectively), and CD86 (MCA1118F, Bio-Rad AbD Serotec, Kidlington, Oxford), CD80 
AlexaFluor 647 (MCA 2071A Bio-Rad AbD Serotec), CD64 and CD16 PerCP 16 
(Pharmingen, 561194 and 5655421) or isotype control antibodies (BD Pharmingen, 
345815, 345817) and 1 ng/ml propidium iodide in 0.5 ml.  Conjugated F-actin was 
stained with fluorescein phalloidin (F432, Invitrogen) added at 1.5ug/ml in 0.01% 
saponin/1% mouse serum /PBS for 30 minutes at room temp. The coverslips were then 
washed in 0.01% saponin/PBS, again in PBS, and mounted on glass slides in one drop 
of Dako fluorescent mountant with a spot of no 2 strength nail varnish at each corner of 
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the coverslip to preserve cell height. Confocal images were acquired on a Zeiss LMI 501 
microscope and analysed with BioRad Lasersharp software.  
 
Ultrastructure studies were performed on cells fixed by immersion in 4% 
glutaraldehyde/2% glutaraldehyde in cold PBS to 15 min. Cells were washed in PBS and 
placed in 1% osmium tetroxide dissolved in 1 mM cacodylate buffer, pH 7.5 for 1 hr at 
room temperature. The samples were dehydrated through an increasing ethanol series, 
staining in 2% uranyl acetate in 30% ethanol in the process and embedded in TAAB 812 
resin (TAAB Laboratories Equipment Ltd, Aldermaston). Ultrathin sections were cut on a 
Leica UCT ultramicrotome and floated onto Formvar-supported grids that were then 
contrasted with uranyl acetate and lead citrate. Micrographs were taken on Zeiss M-10 
electron microscope. 
 
Statistical analysis 
Statistical analyses were performed using SPSS for Windows. Levels of cytokines and 
numbers of cells expressing surface molecules were tested using an independent 
sample two-tailed t-test (assuming normal distribution of data), and by the Mann–
Whitney test for nonparametric data. Spearman’s Rho test was used to assess 
correlation. P-values < 0·05 were considered significant.  
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Results 
Morphology And Formation Of Giant Cells 
Culture of PBMCs from either healthy or CVID patients with GM CSF and IL4 over 7 
days results in a small proportion of giant cells with multiple nuclei. Characteristics of 
these pleomorphic cells are shown in Figure 1: they have an extended cytoplasmic 
border surrounding a central zone containing 2 to 20 nuclei amid dense granular 
inclusions (Figure 1A). The upper surface was frequently attached to rounded monocytic 
cells at various stages of fusion. Nuclei were not incorporated in a symmetrical or 
uniform pattern but appear to accumulate randomly in a central zone (Figure 1B). In the 
absence of GM CSF or IL4 purified CD14+ monocytes formed CD68+ dome shaped 
cells with large central single nuclei in cobblestone formation typical of macrophages 
(data not shown). CD3+T cells or CD19+ B cells added to CD14+ purified monocytes 
restored the formation of giant cells but were not themselves incorporated into the giant 
cells. Monocytes cultured in plastic wells with GM CSF and IL-4 formed multinucleated 
giant cells but when seeded over a monolayer of epithelial and fibroblast cells (A549, 
NIH 3T3, 293T, Meso 33), or implanted in an artificial matrix of agar and matrigel, failed 
to fuse. Coating plates with collagen, BSA or poly- L-lysine increased the fusion rate 
negligibly (data not shown).  
 
Kinetics Of Giant Cell Formation In CVID 
When monocytes from CVID patients were cultured with GM CSF and IL4  
multinucleated cells were observed after day 2 of culture (Figure 1C), increased till day 5 
(Figure 1D) and were generally complete by day 7 of culture. The fusion rate of adherent 
monocytes was examined in cultured cells from 9 CVID and normal individuals over 9 
days of incubation in GM CSF and IL4. Figure 2A shows there was a 2.2 fold average 
higher number of giant cells at day 9 with CVID monocytes when compare to cells from 
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healthy controls, although there was wide variation between cells from different patients. 
Furthermore, the cells from CVID patients formed multinucleate cells with a mean 
number of 77.3 per 10 high power fields (range 23 to 130) compared with mean of 34.0 
(range 13 to 46) nuclei in normal multinucleate cells (p = 0.002; Figure 2A).  The rate of 
cell fusion in CVID cell samples was both faster and greater, resulting in more 
multinucleated cells that were formed earlier than in cultures of normal cells (Figure 2B). 
Sequential observation of plates indicated that after day 3 of culture, the increase in 
multinucleate cell number occurred largely by addition of further cells or by combination 
of already formed giant cells.  
 
The Influence Of Plasma, Cytokines And Immunoglobulins On Giant Cell 
Formation Differed For Normal and CVID Cells.  
The effect of immunoactive agents was evaluated on normal and CVID adherent 
monocytes (Figure 3A) and CD14+ cells (Figure 3B), seeded in triplicate in 24 well plates 
at a density of 5x 105 /ml, stained in Wrights stain to assess the fusion index on day 7 of 
culture. The basal rate of giant cell formation in autologous plamsa was low in normal 
adherent monocytes (mean fusion index 2.55 +/- 0.51 standard deviation (mean FI+/-SD) 
and an average of 1.93 fold higher (4.92 +/- 0.9, mean FI+/-SD) with 9 CVID individuals 
(Figure 3A), ranging from 0.95 to 3.1 fold higher (P = 0.002). When added in a range of 
concentrations, a number of inflammatory cytokines and mitogenic stimuli greatly 
augmented fusion of both normal and CVID PBMCs, but to differing degrees. Several 
cytokines, including IFN  and IL10 had a negligible effect on the basal rate of 
multinucleation of CVID and normal cells (n = 3) and data are not shown. Both GM CSF 
and IL4, individually enhanced fusion indices in normal monocytes (6.8 +/- 1.4 and 8.1 
+/- 1.9, mean FI+/-SD, respectively, n = 6), increases of 2.6 and 3.2 fold, respectively, 
over the normal basal fusion index without reagents. CVID cell fusion indices with GM 
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CSF and IL4, (9.3 +/- 5.9 and 13.7  +/- 3.7 FI+/-SD, respectively, n = 6) were 1.9 and 2.8 
fold higher than CVID basal rates. Induction of multinucleate cells by a combination of 
GM CSF and IL4 was additive, together generating 3.9 and 4.8 fold increases in the 
fusion index of CVID and normal monocytes (n = 6), respectively, over the basal rates 
without cytokines. CVID fusion indices with GM CSF and or IL4 were higher than normal 
cells (P = 0.005) but the induction of cell fusion rates over the basal untreated cell fusion 
indices by these cytokines concentrations was less powerful for CVID cells than for 
normal adherent monocytes. TNF, IFN and IL1 were all active in promotion of 
multinucleate normal cells generating mean fusion indices of 8.7, 9.6  and 8.6 (Figure 
3A), respectively,  3.4 fold, 3.8 and 3.4 fold increases, respectively, over the normal 
basal fusion index without reagents. With CVID cells, TNF, IFN and IL1, promoted 
mean fusion indices of 13.6, 16.6 and 5.1, respectively, 2.8 fold, 3.4 and a relatively low 
1.04 fold increase for IL1a of multinucleate CVID cells over basal fusion index. In normal 
cells, both IL1 and TNF had a synergistic effect with IFN, promoting an additional 1.9 
and 1.4 fold increase in the fusion index over IFN alone whereas in CVID cells (n = 4), 
TNF had a minor synergistic effect with IFN, promoting an additional 0.4 fold increase 
in the fusion index over IFN alone, but the addition of IL1a alone or when combined with 
IFN did not add to fusion of CVID cells (data not shown).  
 
CVID T Cell Response To Anti-Inflammatory Agents and Mitogens Differed From 
Normal.  
Incubation of cultured cells in anti-TNF antibody reduced the mean basal fusion index 
of normal cells by up to a half (mean 51.2%, range 38 to 58%, n = 5) and IL4 +GM CSF 
cultured cells by more than a third (mean 40.3% reduction, range 31 to 48%). CVID 
PBMC basal fusion rate was less affected by anti-TNF antibody (mean 26.8% 
reduction, range 20 to 29%) than normal cells (P = 0.42) while IL4 + GM CSF cultured 
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cells fused 24.2% (range 17 to 28%, n = 6) less frequently in anti-TNF antibody. 
Mitogenic stimulation of adherent mononuclear cells with PMA (10 ng/ml) and  PHA were 
highly active in formation of giant cells from normal monocytes (n = 5), while PHA (5 to 
20 ng/ml) and CD3 antibody stimulation (data not shown) induced a relatively low 
response on CVID monocytes. 
 
Conditioned Media From Purified T Cells And Monocytes Generated 
Disproportionate Results From Normal and CVID Monocytes.  
Normal CD14+ cells cultured in X vivo 15 medium supplemented with 50% PBS or heat 
treated AB serum had low fusion indices (0.7 +/- 0.06 and 1.7 +/- 0.6 mean FI +/- SD, 
respectively, n = 4 normal individuals) with CVID CD14+ cells generating almost 3 fold 
higher rates of multinucleate cells (2.2 +/- 1.5 and 3.8 +/- 1.2 mean FI +/- SD, 
respectively, n = 5 CVID individuals), as shown in Figure 3B. Levels of giant cells 
generated by conditioned media, except those of CVID cells generated with PHA and  
CD3 antibody,  exceeded those of single or combinations of cytokines. T cell conditioned 
media generated from normal and CVID cells with PMA (nPMA and cPMA) were equally 
as effective in promoting cell fusion in CVID cells (25.4 +/- 6.3 and 23.7 +/- 8.1 mean FI 
+/- SD, n = 5 normal cells with nPMA and cPMA, respectively), and also showed 
approximately equivalent but less activity with normal CD14+ cells (18.8 +/- 1.6 and 17.1 
+/- 3.2 mean FI +/- SD, n = 5 CVID individuals, nPMA and cPMA, respectively). CD3 
generated conditioned media of normal cells (nCD3, Figure 3B) also had potent effects 
on the fusion indices of CVID cells and less effect with normal cells (20.6 +/- 4.8 and 
14.6 +/- 5.7 mean FI +/- SD, n = 5 normal and CVID individuals, respectively). CD3 
generated conditioned media with CVID cells (cCD3) was also relatively more effective 
with CVID CD14+ cells but was less potent than other conditioned media (12.9 +/- 4.8 
and 10.6 +/- 2.4 mean FI +/- SD, n = 5 CVID and normal individuals, respectively).  
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Conditioned medium generated with PHA from normal cells was highly potent and again 
relatively more effective with CVID CD14+ cells (nPHA FI +/- SD = 23.4 +/- 4.6 and 17.8 
+/- 4.0, n = 6 normal and CVID individuals, respectively) while conditioned medium 
generated with PHA from CVID cells was much less effective with either normal or CVID 
CD14+ cells (cPHA FI +/- SD = 11.7 +/- 2.1 and 11.2 +/- 3.1, n = 5 normal and CVID 
individuals respectively. The use of monocyte media conditioned with gamma globulin 
also demonstrated a difference between normal and CVID cells. Monocyte conditioned 
media produced by normal cells (nIVIg) generated only marginally more giant cells than 
basal levels but media from CVID monocytes stimulated with IVIg generated 3.9 and 4.9 
fold increases in fusion index of normal and CVID cells, respectively, (10.3 +/- 2.9 and 
14.8 +/- 5.3 mean FI +/- SD, n = 6 normal and CVID individuals, respectively) over 
plasma alone.  
 
 
Giant Cell Function  
Centrifugation of monocytes cultured with GM CSF and IL4 onto coverslips in tissue 
culture plates promoted formation of very large giant cells. Optimal plasticity in fusion in 
both normal and CVID cells occurred after 2 to 3 days and before day 5 of culture. The 
arrangement of nuclei in these large giant cells (Figure 4) was predominantly central but 
seldom symmetrically or circularly organized. Peripheral nuclei continued to fuse with the 
main body after the initial fusion event, but newly incorporated nuclei were not 
repositioned. 1 um confocal optical slices in phalloidin FITC treated cells (Figure 4B) 
show the nuclei to be scattered in the cytoplasm in an irregular arrangement at varying 
heights above the substrate. Central nuclei were embedded in an intricate meshwork of 
F-actin microfibrils, while peripheral nuclei were associated with larger actin microfibers. 
Preincubation of monocytes in phalloidin oleate reduced syncytial formation and resulted 
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in widely dispersed nuclei, implicating actin mediated transport in the rearrangement of 
nuclei in giant cells. Inhibition of syncytia in both CVID and normal cells was also 
dependent on the concentration of cytochalasin D in the medium; 10 mM cytochalasin D 
reduced CVID and normal mean cell fusion 3.2 +/- 1.6% and 4.6 +/- 2.3%, respectively, 
20 mM cytochalasin D 46.4 +/- 8.8% and 41.1 +/- 7.3%, respectively, and 40 mM 
cytochalasin D 73.6 +/- 11.3% and 71.9 +/- 12.8%, respectively, from levels without 
cytochalasin D, in 3 separate experiments. Both normal and CVID giant cells giant cells 
expressed MHC class II DR, CD80, CD86 and CD64 by immunofluorescence but not 
CD14, CD16 or CD83. Expression of class II DR was less intense than undifferentiated 
monocytes stained in equivalent circumstances but no consistent difference were noted 
in marker expression between CVID and normal giant cells. 
 
Examination of giant cells in transverse electron microscopy (Figure 5A) showed many 
small dense mitochondria with well-developed cristae amid rough-surfaced endoplasmic 
reticulum (RER) associated with the nuclei. The cytoplasm was crowded with dense 
lysosomal bodies, microfibrils, microtubules and lipid droplets mingled with the 
mitochondria. Granular vesicles were frequently associated with membrane whorls and 
toriodal structures (Figure 5B), indicating intense membrane reorganization. Golgi 
apparati, centrosomes and free ribosomes were evident but no structural features 
particular to either normal or CVID giant cells were discerned. 
 
Giant cells generated in culture were highly phagocytic, engulfing uncoated and 
opsonized yeast and bacteria. Figure 5C shows a single CVID giant cell with a large 
number of ingested yeast particles at various stages of digestion. When re-exposed to 
yeast particles a day or more later, giant cells would incorporate more particles. Both 
normal and CVID giant cells incorporated sufficient quantities of carboxylated beads to 
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distort the cellular shape and contents (Figure 5D). Trypsinized bead-treated cells 
examined by flow cytometry showed an inverse relationship between the numbers of 
nuclei and the numbers of beads incorporated (data not shown) but it was not possible to 
demonstrate a difference in phagocytic capacity of normal and CVID monocytic syncytia 
with fluorescent bacteria, opsonized or uncoated yeast or carboxylated beads. 
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Discussion 
Giant cells are formed from monocytes in response to a variety of stimuli and in certain 
inflammatory diseases (Heresbach et al., 2005; Mizumo et al., 2000). Formation of 
multinucleate cells from peripheral monocytes in vitro is related to granulomatous 
disease in sarcoid (Mizumo et al., 2001).  The tendency of untreated PBMC from CVID 
individuals to form giant cells in culture was almost twice (1.93 fold on average) that of 
normal cells. Cell fusion varied greatly between CVID individuals with approximately half 
of the CVID samples examined forming giant cells at a rate within the normal range and 
others demonstrating a capacity four or more fold higher than normal cells. Higher fusion 
indices were not closely associated with CVID classification or antibody concentration 
and were related to B and T cell concentration. Chronic inflammation in CVID has been 
associated with low T cell counts and is related to a deficiency in regulatory T cells 
(Fevang et al., 2007) while those CVID individuals with reduced CD19+ cells and the 
lowest switched B cell memory cell counts are most prone to autoimmune phenomena 
and granulomatous disease (Yong, Orange and Sullivan, 2010).    
 
Phenotypic markers of giant cells were indistinguishable in normal or CVID giant cells 
and similar to monocyte-derived DCs but lacked CD83 expression. Multinucleate 
epithelioid cells in granulomatous centres similarly contain large amounts of granules, 
mitochondria, smooth endoplasmic reticulum and free ribosomes (Kirkpatrick, Curry and 
Bisset, 1988) indicating active metabolic capacity. Frequently observed membrane 
complexes have been associated with reorganisation and are consistent with plasma 
membrane vesicle reduction in fused cells. Both normal and CVID giant cells were 
phagocytic and capable of killing engulfed bacteria and yeast cells. The inverse 
relationship between the numbers of nuclei and the numbers of beads incorporated by 
phagocytic giant cells suggests that more mature giant cells were proportionally less 
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phagocytic than monocytes. Phalloidin staining showed centralised nuclei embedded in a 
diffuse network of actin microfilaments whereas peripheral nuclei were often linked to 
larger bundles of fibres. Phalloidin oleate, a cell permeable inhibitor of stable actin 
formation, and cytochalasin D which affects actin filament elongation (Bear et al., 2002) 
prevented nuclear aggregation and reduced the fusion index, suggesting that actin 
microfilament elongation enabled nuclear reorganisation in giant cells and has a role in 
cell fusion. 
 
CVID giant cells had higher number of nuclei and were formed earlier in culture than 
normal giant cells. Accumulation of multicellular nuclei in later stages of culture occurred 
largely by amalgamation of adjacent giant cells or further incorporation into established 
giant cells rather than continued fusion between single cells, implying that a limited 
number of cells in culture were capable of fusion in vitro and that these cell continued to 
be active in fusion at subsequent times. IL4 and GM CSF concentrations suitable for 
generating monocyte derived DC, boosted the fusion rates 2 to 3 fold and acted additively 
(Dugast, Gaudi and Toujas, 1997), augmenting the formation of giant cells up to 5 fold 
over the basal rates in both normal and CVID cells. Inflammatory lymphokines, particularly 
IFN and TNF, dramatically induced the fusion rates in both normal and CVID 
monocytes, in keeping with previous findings that IFN is pivotal in giant cell formation 
(Most et al., 1990; Fais et al., 1994). IFN also acted additively with other cytokines in 
promoting syncytia (Byrd, 1998); combinations of IFN with IL4 or GM CSF generating the 
highest fusion indices, over 5.5 or 6 fold the unstimulated monocyte fusion rates in CVID 
and normal cells, respectively, indicating that monokines and lymphokines can cooperate 
in monocyte fusion in normal and CVID cells alike. The reduction in giant cell formation in 
some CVID cell samples the presence of IL10, which acts to reduce cytokine synthesis by 
monocytes (de Waal et al., 1991), would suggest that monocyte cytokine production can 
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promote granuloma in CVID as supported by the potent fusogenic activity of CD14+ cell 
conditioned media. T cell mitogens were also potent inducers of normal as well as CVID 
fusion of monocytes and the equivalent activity of T cell and monocyte conditioned media 
in generating fusion of purified CD14 cell populations would indicate that both 
lymphokines and monokines are both sufficient to generate fusion. Similarly, supernatants 
from mitogen-stimulated PBMC were the major stimulus to fusion of normal monocytes 
(Postlethwaite et al., 1982) and were as effective inducers of cellular fusion as optimized 
cytokine concentrations when added to monocytes isolated from individuals with sarcoid 
(Most et al., 1997). It is likely that monocytes and lymphocytes, and possibly other cells in 
vivo, produce cytokines that synergise in promoting granuloma formation. Th1 cells, 
producing INF (Wahlstrom et al., 2001), probably aggregate in response to IL12 
production by APCs (Rissoan et al., 1999), leading to TNF production (Grunewald and 
Eklund, 2007) and further promotion of IL12 production in a pro-inflammatory loop in 
granulomatous foci. The importance of IFN in T cell recruitment and macrophage 
activation has been demonstrated in a mouse model where deficiency in IFN production 
prevents granuloma formation (Pearl et al., 2001). CVID T cells synthesize more IFN and 
CVID monocytes higher amounts of IL12 than healthy individuals when stimulated with 
LPS (Cambronero et al., 2000), contributing to a Th1 cytokine milieu that would mitigate 
against B cell class switching and antibody production. 
 
Higher numbers of multinucleate cells and more nuclei per giant cell were generated in 
the CVID cell samples. However, the basal fusion index of untreated normal PBMC was 
augmented more by addition of IFNTNF and T cell mitogens than was the basal 
fusion rate of CVID cells. These observations would suggest that activated CVID 
peripheral monocytes (Scott-Taylor et al., 2006; Barbosa et al.,2012.) are less amenable 
to further cytokine induction in vitro.  The comparatively low stimulus to CVID cell fusion 
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relative to normal cells of IL1 and PHA conditioned media may instead be inherent to 
an early T cell signal transduction defect in immunodeficiency (Zielen et al., 1994; Fiedler 
et al., 1987). The greater reduction of the cytokine induced fusion rate for normal than 
CVID cells by incubation in anti-TNF antibody would indicate that monocyte fusion 
partially acts through TNF and that activation of monocytes in CVID is influential in 
giant cell formation. Elevated serum TNF levels in CVID are related to low CD4+ T cell 
counts (Aukrust et al., 1996) and to autoimmune phenomena (Knight and Cunningham-
Rundles, 2006). A high proportion of CVID individuals with granulomatous disease have 
a TNF receptor mutation that may predispose to inflammatory disease (Mullighan et al., 
1997). Anti-TNF treatment can reduce granulomatous lesions in CVID (Lin et al., 2006; 
Thatayatikom et al., 2005) and classical sarcoid disease (Wells et al., 2008). In vitro anti-
TNF antibody had little effect on the basal monocyte fusion rate but did particularly 
affect the fusion index of CVID cells treated with IL4 and GM CSF. The fusion of normal 
monocytes was inhibited more by anti-TNF treatment than CVID cells, indicating that 
the constitutional activation of CVID peripheral monocytes may make them unamenable 
to anti-TNF antibody treatment and that other factors are involved in monocyte fusion in 
CVID.  
 
The promotion of in vitro fusion by conditioned media of monocytes treated with gamma 
globulin raises the question of whether this standard treatment of CVID may increase the 
risk of granulomatous disease, possibly by enhancing FcRI expression. IVIg therapy 
predominantly reduces inflammatory responses (Sewell et al.,1999; Ballow et al., 1989) 
and suppressed the production of IFN and IL12p70 from B cells (Bayry et al., 2011). 
Nevertheless, increased TNF and TNF receptor expression has been documented to 
IVIg therapy in IgG deficient (Farber et al., 1994) and CVID individuals (Sewell et 
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al.,1999) and correlated with adverse inflammatory reactions (Aukrust et al., 1994).  IVIg 
infusion increased CD64 expression in monocytes (Ling et al., 1993) through 
inflammatory cytokine expression and could contribute to the occurrence of 
granulomatous complications in CVID by promotion monocyte fusion through Fc receptor 
interaction. In summary, this data provides further evidence of a disturbed myeloid 
lineage in CVID that may contribute to pathology in immunodeficiency. Besides the well 
described defects in circulating T cells, constitutional activation of peripheral monocytes 
may explain the predisposition of CVID patients to chronic inflammatory complications 
including granuloma.    
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Figure Legends. 
 
Figure 1:   Appearance Of Multinucleate Cells In Culture. Large multinucleate cells 
appeared in culture of adherent monocytic cells in GM CSF and IL4 (A); in refracted light 
at x20 magnification. (B): stained with MHC class II DR FITC and DAPI. CVID monocytic 
cells PBMC were culture in 24 well plates and stained with Wright’s stain at various 
times. Fused cells with multiple nuclei were evident by day 3  (C) and well advanced by 
day 7 (D) of culture. 
 
Figure 2:  Comparison of  Multinucleate Cell Formation In CVID and Normal Individuals. 
PBMC plated in 6 well plates at a  density of 5 x 105 cells per ml in GM CSF and IL4 and 
examined under a bright field microscope.  Cell fusion was enumerated in 10 high power 
fields. Data displayed as A: mean (      ), 25 to 75%  (      ) and complete range (      ) of 
the fusion index of normal and CVID cells of 9 individuals. B: individual fusion rates of 
CVID  patients ( X and dashed lines               ) overlap with the fusion rate of normal 
individuals    ( mean multinucleate cells of nine individuals +/- standard deviation, 
complete lines            ) but normal fusion rates were lower and more consistent.  
Statistical evaluation was performed by Student T test. 
 
Figure 3:  Multinucleate Cell Formation in Normal and CVID Cells To A Variety Of Stimuli.  
A: Peripheral blood mononuclear cells were cultured for 7 days in a range of 
concentrations of cytokines and mitogens or with anti-TNF antibody and the fusion index 
generated as (the number of nuclei in multinucleate cells) / (total number of nuclei 
counted) x100. Results are expressed as the mean +/- the standard deviation of 3 or more 
individuals. PBMC of CVID patients had a higher capacity to generate multinucleate cells 
to different stimuli  and growth conditions than those of healthy controls. B:  CD14+ cells 
were cultured in X vivo 15 medium supplemented with PBS, or pooled human AB serum, 
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or conditioned medium from normal or CVID cells treated with OKT3 antibody (nCD3 and 
cCD3) or stimulated with PMA (nPMA and cPMA) or PHA (nPHA and cPHA) or pooled 
human immunoglobulin (nIVIg and cIVIg).        = normal  cells,        =  CVID cells. Fusion 
indices represent 3 or more separate experiments. Statistical values generated by Mann 
Whitney U test. *P = 0.05, **P = 0.01.  
 
Figure 4:  Arrangement of Nuclei In Giant Cells. A: stained with phalloidin FITC and DAPI 
on day 7 of culture after induction of cell fusion of CVID PBMC by centrifugation of IL4 
and GM CSF incubated cells, B: 1 um optical slices of the same cell showing a central 
nuclei mass surrounded by an intricate microfibril mesh. 
 
Figure 5:  High Magnification Examination of CVID Giant Cells. A:   Transmission 
electron micrograph of a giant cell (x5390) illustrating mitochondria (M), dense granules 
(G) and rough endoplasmic reticulum (ER) closely associated with nuclei (N). Scale bar, 
5 um. B:  detail of cytoplasm (x23400) of a CVID giant cell showing numerous 
mitochondria (M), endoplasmic reticulum (ER) and free ribosomes (R). The toroidal 
structures (arrow) indicate active membrane reorganisation. Scale bar, 500 nm. C:  
Electron micrograph of a giant cell with numerous yeast cell bodies (arrow) at various 
stages of digestion. D: confocal microscope illustration of a CVID ingested carboxylated 
beads (arrow). Fluorescent latex beads of 5 um in diameter were added on day 7 for 4 
hours to monocytes cultured at a density of 106 cell per well in a 24 well plate in 100 mM 
GM CSF and IL4 prior to fixation and staining. Numerous beads (arrow) show up as 
regular array . 
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Table 1:  Patient Immunoglobulin and Lymphocyte Phenotype. 
Patient Sex Age IgG 
mg/dl 
IgA 
mg/dl 
IgM 
mg/dl 
CD3+ 
x10
9
/L 
CD19+ 
x10
9
/L (*)  
Fusion 
Index 
CMV 
status 
Clinical 
Presentation 
1 F 48 0.1 <0.1 <01 2.04 0.03 (1a) 37.3 + bronchiectasis 
 F 56 1.5 <0.1 <0.1 1.93 0.03  (1b) 49.2 + bronchiectasis, 
enteropathy 
3 M 75 1.6 0.3 0.2 0.84 0.05    (1a) 52.6 + granulomatous 
liver disease 
4 M 63 1.0 <0.1 0.7 1.05 0.22   (1b) 16.3 -  
5 M 37 0.1 0.1 0.2 1.98 0.23  (1b) 11.5 - bronchiectasis, 
enteropathy 
6 F 61 0.6 <0.1 0.15 1.29 0.24  (1a) 17.7 +  
7 F 55 2.2 0.98 0.41 2.5 0.28  (1a) 18.6 + bronchiectasis, 
enteropathy 
8 F 26 3.7 <0.1 0.4 0.94 0.28  (1b) 16.7 -  
9 F 43 2.9 0.1 0.6 1.54 0.29  (1a) 14.5 - granulomatous 
liver disease 
10 F 42 4.4 0.1 0.2 1.38 0.29  (1b) 10.8 + bronchiectasis 
11 F 52 8.8 0.1 0.4 0.72 0.35  (1b) 26.1 nd bronchiectasis 
12 F 40 2.9 0.42 1.0 1.62 0.36  (1b) 11.3 +  
13 M 48 3.3 <0.1 1.12 0.76 0.38  (1b) 16.2 -  
14 F 70 3.8 0.5 4.6 1.28 0.5    (1b) 12.8 +  
15 F 52 1.1 <0.1 0.2 1.69 1.02  (1a) 48.6 - granulomatous 
disease, 
bronchiectasis 
16 F 59 0.64 <0.1 0.4 2.65 1.11    (1a) 37.4 + granulomatous 
liver disease 
17 F 41 0.9 <0.1 <0.1 1.40 nd 34.5 + bronchiectasis 
18 M 49 0.8 0.8 <0.1 0.78 0.003 (1b) 21.3 -  
19 F 51 0.8 <0.1 <0.1 1.01 0.02    (1b) 24.7 nd  
20 F 56 1.4 <0.1 <0.1 1.75 0.33    (1a) 18.6 nd  
21 F 52 0.9 <0.1 0.4 0.73 0.16 (1b) 23.1 + bronchiectasis, 
enteropathy, 
granuloma 
22 M 22 0.8 <0.1 <0.1 0.55 0.05 (1a) 15.8 +  
23 F 42 1.1 <0.1 <0.1 1.65 nd 41.0 + bronchiectasis 
24 F 31 2.9 0.2 0.5 1.4 0.35 (1a) 38.9 + granulomatous 
liver disease 
R
2•
   0.023 0.046 0.13 0.022 0.012    
P   0.9 0.83 0.53 0.91 0.96  0.28^  
* Freiberg classification.    • R2 correlation to fusion index.   
^P value for unpaired T test comparing fusion indices of CMV positive and negative patients 
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Fig. 1 
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Fig. 2 
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Fig. 3 
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Fig. 4 
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Fig. 5 
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Highlights 
 
 The optimal generation of giant cells is described. 
 Monocytes from CVID have elevated fusion rates. 
 Fusion indices of monocytes of CVID individuals was not related to CMV status, T or B cell 
numbers or immunoglobulin concentrations. 
 Anti TNFa treatment did not reduce giant cell formation in CVID monocytes  but immunoglobulin 
conditioned monocyte media did promote giant cell formation. 
 Monocyte disturbances  and possibly standard treatment via IVIg contribute to inflammatory 
pathology  in CVID. 
